Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Multicenter Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 in Adult Subjects With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency Who Previously Received Treatment in Study LAL-CL01

NCT01488097 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01488097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01488097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Multicenter Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 in Adult Subjects With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency Who Previously Received Treatment in Study LAL-CL01
Lead sponsor
Alexion Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 12, 2011
Completion date
June 21, 2017
Enrollment
8 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

cholesterol ester storage disease (cesd), lal-deficiency, lysosomal acid lipase deficiency